Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case–Control Study

Annals of Surgical Oncology

Volumn 22, Issue , 2015, Pages 502-508

  Collins, Laura C ^a,b   Achacoso, Ninah ^c   Haque, Reina ^c   Nekhlyudov, Larissa ^b,d,e   Quesenberry, Charles P ^c   Schnitt, Stuart J ^a,b   Habel, Laurel A ^c   Fletcher, Suzanne W ^b,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c KAISER PERMANENTE   (United States)

^d HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^e HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CONSERVING THERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CASE CONTROL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE PRACTICE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PREDICTION; SURGICAL PATIENT; TUMOR INVASION; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMPARATIVE STUDY; MIDDLE AGED; NOMOGRAM; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; PROGNOSIS; RISK ASSESSMENT;

EID: 84952875435     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4641-x     Document Type: Article

References (28)

1. Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJ. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol. 2008;15(1):235–43.
2. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381–7.
3. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95(22):1692–702.
4. Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103(6):1137–46.
5. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001;19(8):2263–71.
6. Solin LJ, McCormick B, Recht A, et al. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Cancer J Sci Am. 1996;2(3):158.
7. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001;28(4):400–18.
8. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.
9. Goldstein NS, Kestin L, Vicini F. Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy. Am J Surg Pathol. 2000;24(8):1058–67.
10. Vicini FA, Kestin LL, Goldstein NS, et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol. 2000;18(2):296–306.
11. Van Zee KJ, Liberman L, Samli B, et al. Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer. 1999;86(9):1757–67.
12. Schnitt SJ. Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr. 2010;2010(41):158–61.
13. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762–9.
14. Yi M, Meric-Bernstam F, Kuerer HM, et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012;30(6):600–7.
15. Sweldens C, Peeters S, van Limbergen E, et al. Local relapse after breast-conserving therapy for ductal carcinoma in situ: a European single-center experience and external validation of the Memorial Sloan-Kettering Cancer Center DCIS nomogram. Cancer J. 2014;20(1):1–7.
16. Wang F, Li H, Tan PH, et al. Validation of a nomogram in the prediction of local recurrence risks after conserving surgery for asian women with ductal carcinoma in situ of the breast. Clin Oncol. 2014;26(11):684–91.
17. Habel LA, Achacoso NS, Haque R, et al. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009;11(6):R85.
18. Collins LC, Achacoso N, Haque R, et al. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013;139(2):453–60.
19. Langholz B, Borgan O. Estimation of absolute risk from nested case-control data. Biometrics. 1997;53(2):767–74.
20. Brentnall AR, Cuzick J, Field JR, Duffy SW. A concordance index for matched case–control studies with applications in cancer risk. Stat Med. 2014. doi:10.1002/sim.6335.
21. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26(25):4063–71.
22. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358–66.
23. Van Zee KJ, Patil S. Validation of a nomogram for predicting risk of local recurrence for ductal carcinoma in situ. J Clin Oncol. 2012;30(25):3143–4; author reply 3144–5.
24. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–74.
25. Elmore JG, Fletcher SW. The risk of cancer risk prediction: “What is my risk of getting breast cancer”? J Natl Cancer Inst. 2006;98(23):1673–5.
26. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10.
27. Rakovitch E, Nofech-Mozes S, Hanna W, et al. Abstract S5-04: A large prospectively-designed study of the DCIS score: predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation. Cancer Res. 2015. doi:10.1158/1538-7445.SABCS14-S5-04.
28. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102(9):627–37.